Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ES16001 in Patients With COVID-19
NCT05525182Phase 3Unknown
- Sponsor
- GENENCELL
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ES16001 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by GENENCELL. Primary endpoint: Proportion of participants who required oxygen therapy, invasive or non-invasive mechanical ventilation, or died due to worsening of COVID-19 at Day 29. Status: unknown.
02
Drugs
ES16001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05525182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525182.